Search

Displaying results 5211 - 5220 of 10000 in total
  1. Drug

    Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15708
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15712
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    PCSK9 binds low-density lipoprotein receptors (LDLR) on the surface of hepatocytes and promotes their degradation within the liver; by blocking this interaction, enlicitide increases the number of LDLRs … Enlicitide is a macrocyclic peptide inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9).

  5. Drug

    Naproxcinod

    go.drugbank.com/drugs/DB06682
    Investigational

    Synonyms: Naproxen-N-butyl nitrateCategories: Antiinflammatory and Antirheumatic Products, Non-Steroids
  6. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  7. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  8. Drug

    Coumazoline

    go.drugbank.com/drugs/DB21226
    Experimental

    Coumazoline has a monoisotopic molecular weight of 228.13 Da. … The usage of the INN stem '-azoline' in the name indicates that Coumazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.

  9. Drug

    Domazoline

    go.drugbank.com/drugs/DB19937
    Experimental

    Domazoline has a monoisotopic molecular weight of 248.15 Da. … The usage of the INN stem '-azoline' in the name indicates that Domazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.

  10. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).